View larger version (62K):
[in this window]
[in a new window]
|
Figure 1. A genetically engineered, humanized antibody against CD25 (Tac, the interleukin-2–receptor  chain) was labeled with indium-111 and administered to a patient with CD25+ B-cell lymphoblastic leukemia at a dose of 1 mg per kilogram of body weight. The white-cell count decreased from 44,000 per cubic millimeter (80 percent blasts) to 11,000 per cubic millimeter (65 percent blasts) 3 hours after the intravenous infusion, with a further reduction over the next 16 hours. Nuclear scanning at 48 hours showed a marked redistribution of the antibody from the blood (indicated by the absence of visible cardiac and vascular structures on the scan) to . . . [Full Text of this Article] |
Previous
